oxybutynin has been researched along with Prostatic Hyperplasia in 7 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
Prostatic Hyperplasia: Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although the anticholinergic dosage was low, the present results suggest that naftopidil monotherapy was as useful as combination therapy of naftopidil and an anticholinergic agent." | 6.72 | Naftopidil monotherapy vs naftopidil and an anticholinergic agent combined therapy for storage symptoms associated with benign prostatic hyperplasia: A prospective randomized controlled study. ( Hanazawa, K; Honda, S; Kawachi, Y; Koizumi, K; Maruyama, O; Noto, K; Saitoh, T; Sugimura, S; Sugiyama, Y; Yamashita, R, 2006) |
| "To evaluate the symptomatic and urodynamic effects of oxybutynin in the control of irritative micturitional symptoms during the first week after transurethral resection of benign prostatic hyperplasia (BPH)." | 5.08 | Oxybutynin in the treatment of early detrusor instability after transurethral resection of the prostate. ( Borst, F; Graber, P; Iselin, CE; Rohner, S; Schmidlin, F, 1997) |
| "2%) reported no treatment-related adverse events; two men (0." | 2.73 | Effects of oxybutynin transdermal system on health-related quality of life and safety in men with overactive bladder and prostate conditions. ( Dahl, NV; Polishuk, PV; Rosenberg, MT; Staskin, DR; Zinner, NR, 2008) |
| "Although the anticholinergic dosage was low, the present results suggest that naftopidil monotherapy was as useful as combination therapy of naftopidil and an anticholinergic agent." | 2.72 | Naftopidil monotherapy vs naftopidil and an anticholinergic agent combined therapy for storage symptoms associated with benign prostatic hyperplasia: A prospective randomized controlled study. ( Hanazawa, K; Honda, S; Kawachi, Y; Koizumi, K; Maruyama, O; Noto, K; Saitoh, T; Sugimura, S; Sugiyama, Y; Yamashita, R, 2006) |
| "Whether incontinence after surgery for benign prostatic hypertrophy (BPH) requires simple workup and treatment or being a more complex condition and multifactorial in etiology requiring combined surgical techniques should be investigated in more detail." | 1.30 | Incontinence after surgery for benign prostatic hypertrophy: the case for complex approach and treatment. ( Floratos, D; Katsifotis, C; Mertziotis, N; Moutzouris, G; Plastiras, D; Theodorou, C, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Shah, AA | 1 |
| Kumar, P | 1 |
| Ogunmola, AG | 1 |
| Ayyash, O | 1 |
| Yabes, JG | 1 |
| Sabik, LM | 1 |
| Odisho, AY | 1 |
| Bandari, J | 1 |
| Macleod, LC | 1 |
| Davies, BJ | 1 |
| Jacobs, BL | 1 |
| Hakimi, Z | 1 |
| Johnson, M | 1 |
| Nazir, J | 1 |
| Blak, B | 1 |
| Odeyemi, IA | 1 |
| Barkin, J | 1 |
| Diles, D | 1 |
| Franks, B | 1 |
| Berner, T | 1 |
| Maruyama, O | 1 |
| Kawachi, Y | 1 |
| Hanazawa, K | 1 |
| Koizumi, K | 1 |
| Yamashita, R | 1 |
| Sugimura, S | 1 |
| Honda, S | 1 |
| Sugiyama, Y | 1 |
| Saitoh, T | 1 |
| Noto, K | 1 |
| Staskin, DR | 1 |
| Rosenberg, MT | 1 |
| Dahl, NV | 1 |
| Polishuk, PV | 1 |
| Zinner, NR | 1 |
| Iselin, CE | 1 |
| Schmidlin, F | 1 |
| Borst, F | 1 |
| Rohner, S | 1 |
| Graber, P | 1 |
| Theodorou, C | 1 |
| Moutzouris, G | 1 |
| Floratos, D | 1 |
| Plastiras, D | 1 |
| Katsifotis, C | 1 |
| Mertziotis, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prophylactic Tamsulosin in Prevention of Post-operative Urinary Retention in Men After Transanal Endoscopic Microsurgery: A Multicenter Randomized, Double-blind, Placebo-controlled Clinical Trial[NCT03314025] | Phase 2 | 158 participants (Anticipated) | Interventional | 2017-10-06 | Recruiting | ||
| Multicenter Assessment of Transdermal Therapy in Overactive Bladder With Oxybutynin TDS (MATRIX)[NCT00224146] | Phase 4 | 2,878 participants (Actual) | Interventional | 2004-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for oxybutynin and Prostatic Hyperplasia
| Article | Year |
|---|---|
Naftopidil monotherapy vs naftopidil and an anticholinergic agent combined therapy for storage symptoms associated with benign prostatic hyperplasia: A prospective randomized controlled study.
Topics: Adrenergic alpha-Antagonists; Aged; Benzilates; Cholinergic Antagonists; Drug Therapy, Combination; | 2006 |
Effects of oxybutynin transdermal system on health-related quality of life and safety in men with overactive bladder and prostate conditions.
Topics: Administration, Cutaneous; Adult; Aged; Health Status Indicators; Humans; Male; Mandelic Acids; Midd | 2008 |
Oxybutynin in the treatment of early detrusor instability after transurethral resection of the prostate.
Topics: Aged; Double-Blind Method; Humans; Male; Mandelic Acids; Middle Aged; Parasympatholytics; Postoperat | 1997 |
4 other studies available for oxybutynin and Prostatic Hyperplasia
| Article | Year |
|---|---|
Statewide Price Variation for Generic Benign Prostatic Hyperplasia Medications.
Topics: Costs and Cost Analysis; Drugs, Generic; Finasteride; Humans; Male; Mandelic Acids; Pennsylvania; Pr | 2021 |
Drug treatment patterns for the management of men with lower urinary tract symptoms associated with benign prostatic hyperplasia who have both storage and voiding symptoms: a study using the health improvement network UK primary care data.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Benzhydryl Compounds; Cresols; Family Practice; Human | 2015 |
Alpha blocker monotherapy versus combination therapy with antimuscarinics in men with persistent LUTS refractory to alpha-adrenergic treatment: patterns of persistence.
Topics: Administrative Claims, Healthcare; Adrenergic alpha-Antagonists; Aged; Benzofurans; Doxazosin; Drug | 2015 |
Incontinence after surgery for benign prostatic hypertrophy: the case for complex approach and treatment.
Topics: Aged; Aged, 80 and over; Follow-Up Studies; Humans; Incidence; Male; Mandelic Acids; Middle Aged; Pr | 1998 |